Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Taysha Gene Therapies' Other Non-Current Liabilities fell 9644.84% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 9644.84%. This contributed to the annual value of $1.3 million for FY2024, which is 1699.43% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Other Non-Current Liabilities of $1.6 million as of Q3 2025, which was down 9644.84% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Other Non-Current Liabilities peaked at $44.4 million during Q3 2024, and registered a low of $1.2 million during Q1 2025.
  • In the last 4 years, Taysha Gene Therapies' Other Non-Current Liabilities had a median value of $3.8 million in 2023 and averaged $10.6 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Other Non-Current Liabilities soared by 105798.54% in 2024, and later tumbled by 9715.16% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Other Non-Current Liabilities stood at $4.1 million in 2022, then crashed by 61.82% to $1.6 million in 2023, then fell by 16.99% to $1.3 million in 2024, then grew by 20.4% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.4 million for Q2 2025, and $1.2 million during Q1 2025.